Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ZLAB Stock Alerts

Zai Lab (ZLAB) Competitors

Zai Lab logo
$20.98 -0.24 (-1.13%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$21.14 +0.16 (+0.77%)
As of 05/5/2026 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ZLAB vs. PRAX, AXSM, ABVX, PCVX, and NUVL

Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Praxis Precision Medicines (PRAX), Axsome Therapeutics (AXSM), Abivax (ABVX), Vaxcyte (PCVX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Zai Lab compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Zai Lab has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M1,086.44-$303.27M-$13.46N/A
Zai Lab$460.16M5.17-$175.54M-$1.61N/A

In the previous week, Praxis Precision Medicines had 6 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 1 mentions for Zai Lab. Praxis Precision Medicines' average media sentiment score of 0.95 beat Zai Lab's score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Praxis Precision Medicines has a net margin of 0.00% compared to Zai Lab's net margin of -38.15%. Zai Lab's return on equity of -22.81% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -58.74% -53.54%
Zai Lab -38.15%-22.81%-15.04%

Praxis Precision Medicines presently has a consensus price target of $590.78, indicating a potential upside of 77.25%. Zai Lab has a consensus price target of $50.00, indicating a potential upside of 138.32%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
5 Strong Buy rating(s)
3.00
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 5.0% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Summary

Praxis Precision Medicines beats Zai Lab on 9 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Zai Lab has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M17.97-$183.17M-$3.69N/A
Zai Lab$460.16M5.17-$175.54M-$1.61N/A

In the previous week, Axsome Therapeutics had 47 more articles in the media than Zai Lab. MarketBeat recorded 48 mentions for Axsome Therapeutics and 1 mentions for Zai Lab. Axsome Therapeutics' average media sentiment score of 0.47 beat Zai Lab's score of 0.30 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
15 Very Positive mention(s)
11 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Zai Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics has a net margin of -26.59% compared to Zai Lab's net margin of -38.15%. Zai Lab's return on equity of -22.81% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-26.59% -246.90% -29.04%
Zai Lab -38.15%-22.81%-15.04%

Axsome Therapeutics presently has a consensus target price of $251.89, indicating a potential upside of 12.93%. Zai Lab has a consensus target price of $50.00, indicating a potential upside of 138.32%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.90
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 5.0% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Abivax?

Zai Lab (NASDAQ:ZLAB) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -38.15%. Zai Lab's return on equity of -22.81% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-38.15% -22.81% -15.04%
Abivax N/A -146.43%-88.69%

Zai Lab currently has a consensus target price of $50.00, indicating a potential upside of 138.32%. Abivax has a consensus target price of $137.15, indicating a potential upside of 10.80%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63
Abivax
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M5.17-$175.54M-$1.61N/A
AbivaxN/AN/A-$380.27M-$5.37N/A

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Abivax had 6 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Abivax and 1 mentions for Zai Lab. Abivax's average media sentiment score of 1.45 beat Zai Lab's score of 0.30 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Abivax
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Zai Lab beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Vaxcyte?

Zai Lab (NASDAQ:ZLAB) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -38.15%. Zai Lab's return on equity of -22.81% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-38.15% -22.81% -15.04%
Vaxcyte N/A -25.88%-23.85%

Zai Lab has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M5.17-$175.54M-$1.61N/A
VaxcyteN/AN/A-$766.63M-$5.62N/A

Zai Lab currently has a consensus target price of $50.00, indicating a potential upside of 138.32%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 54.69%. Given Zai Lab's higher possible upside, equities analysts clearly believe Zai Lab is more favorable than Vaxcyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vaxcyte had 9 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Vaxcyte and 1 mentions for Zai Lab. Vaxcyte's average media sentiment score of 0.85 beat Zai Lab's score of 0.30 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Zai Lab beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Nuvalent has a net margin of 0.00% compared to Zai Lab's net margin of -38.15%. Zai Lab's return on equity of -22.81% beat Nuvalent's return on equity.

Company Net Margins Return on Equity Return on Assets
NuvalentN/A -39.29% -35.01%
Zai Lab -38.15%-22.81%-15.04%

Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Zai Lab has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvalentN/AN/A-$425.38M-$5.85N/A
Zai Lab$460.16M5.17-$175.54M-$1.61N/A

Nuvalent presently has a consensus target price of $137.25, suggesting a potential upside of 35.26%. Zai Lab has a consensus target price of $50.00, suggesting a potential upside of 138.32%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Nuvalent.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvalent
1 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.88
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 10.2% of Nuvalent shares are held by company insiders. Comparatively, 5.0% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Nuvalent had 9 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Nuvalent and 1 mentions for Zai Lab. Nuvalent's average media sentiment score of 0.67 beat Zai Lab's score of 0.30 indicating that Nuvalent is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvalent
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Nuvalent and Zai Lab tied by winning 8 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZLAB vs. The Competition

Export
MetricZai LabMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.41B$3.40B$6.25B$11.76B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-13.0338.5729.2427.07
Price / Sales5.17280.01504.6873.40
Price / CashN/A125.0643.3053.90
Price / Book3.287.059.676.69
Net Income-$175.54M$23.62M$3.55B$332.64M
7 Day Performance1.11%5.87%3.02%3.07%
1 Month Performance2.34%6.33%5.13%7.80%
1 Year Performance-28.59%78.43%38.78%41.57%

Zai Lab Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
2.5358 of 5 stars		$20.98
-1.1%		$50.00
+138.3%		-32.2%$2.41B$460.16MN/A1,784
PRAX
Praxis Precision Medicines
3.3863 of 5 stars		$330.99
-4.0%		$590.78
+78.5%		+755.5%$9.60B$8.55MN/A110
AXSM
Axsome Therapeutics
3.1576 of 5 stars		$187.41
+0.8%		$218.06
+16.4%		+91.5%$9.51B$638.50MN/A380
ABVX
Abivax
3.1599 of 5 stars		$111.90
-2.3%		$137.15
+22.6%		+1,638.5%$9.08BN/AN/A61
PCVX
Vaxcyte
2.1773 of 5 stars		$59.72
+0.4%		$86.00
+44.0%		+62.2%$8.59BN/AN/A160

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel